Chibale's H3D Centre is one of Africa's top drug discovery labs, with more than 75 staff working on treatments tailored to Africa's genetic diversity.
The team advanced a small-molecule antimalarial drug candidate into clinical trials (conducted in South Africa and Ethiopia); development was later halted due to safety concerns in animal studies.